Cargando…
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
BACKGROUND: Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102). Because some of these studies failed to address immortality time bias, however, their findings should be interpreted with caution. Add...
Autores principales: | Watanabe, Daichi, Fujii, Hironori, Ohata, Koichi, Iihara, Hirotoshi, Makiyama, Akitaka, Kobayashi, Ryo, Hirose, Chiemi, Hishida, Shiori, Matsuoka, Serika, Tajima, Jesse Yu, Kiyama, Shigeru, Takahashi, Takao, Suzuki, Akio, Matsuhashi, Nobuhisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634158/ https://www.ncbi.nlm.nih.gov/pubmed/37940878 http://dx.doi.org/10.1186/s12885-023-11618-3 |
Ejemplares similares
-
Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019) -
Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017) -
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021) -
Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy
por: Fujii, Hironori, et al.
Publicado: (2022) -
A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)